Upgrade to SI Premium - Free Trial

RedHill Biopharma (RDHL)

0.46 -0.05 (9.80%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/1/26)

Latest Headlines

NCI awards $2.9M to study RedHill drug with CAR T-cell therapy October 19, 2026 8:01 AM - StreetInsider $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma October 19, 2026 8:00 AM - PR NewsWire Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs October 1, 2026 6:24 PM - Globe NewsWire RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results September 30, 2026 4:05 PM - PR NewsWire RedHill acquires Ferring's Rebyota and Clenpiq for $12M upfront September 1, 2026 7:00 AM - StreetInsider RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq® September 1, 2026 7:00 AM - StreetInsider RedHill sells Talicia to Apotex for $18M upfront plus milestones August 31, 2026 7:01 AM - StreetInsider RedHill seeks Ebola treatment role for opaganib as cases top 3,200 July 28, 2026 7:02 AM - StreetInsider Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development July 28, 2026 7:00 AM - PR NewsWire Full Article List